CY1125536T1 - Συνθεσεις για τη θεραπεια της αμυλοειδωσης - Google Patents
Συνθεσεις για τη θεραπεια της αμυλοειδωσηςInfo
- Publication number
- CY1125536T1 CY1125536T1 CY20221100542T CY221100542T CY1125536T1 CY 1125536 T1 CY1125536 T1 CY 1125536T1 CY 20221100542 T CY20221100542 T CY 20221100542T CY 221100542 T CY221100542 T CY 221100542T CY 1125536 T1 CY1125536 T1 CY 1125536T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amyloidosia
- compositions
- treatment
- amyloidosis
- patients
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357151P | 2016-06-30 | 2016-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125536T1 true CY1125536T1 (el) | 2025-05-09 |
Family
ID=59351103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100542T CY1125536T1 (el) | 2016-06-30 | 2022-08-08 | Συνθεσεις για τη θεραπεια της αμυλοειδωσης |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190169280A1 (enExample) |
| EP (1) | EP3478713B1 (enExample) |
| JP (3) | JP2019519584A (enExample) |
| CY (1) | CY1125536T1 (enExample) |
| DK (1) | DK3478713T3 (enExample) |
| ES (1) | ES2914781T3 (enExample) |
| HR (1) | HRP20220979T8 (enExample) |
| HU (1) | HUE059400T2 (enExample) |
| LT (1) | LT3478713T (enExample) |
| MA (1) | MA45552A (enExample) |
| PL (1) | PL3478713T3 (enExample) |
| PT (1) | PT3478713T (enExample) |
| RS (1) | RS63446B1 (enExample) |
| SI (1) | SI3478713T1 (enExample) |
| SM (1) | SMT202200261T1 (enExample) |
| WO (1) | WO2018005967A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210017278A1 (en) * | 2018-03-23 | 2021-01-21 | Prothena Biosciences Limited | Treatment and Prophylaxis of Amyloidosis |
| CA3129890A1 (en) * | 2019-02-12 | 2020-08-20 | Prothena Biosciences Limited | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells |
| MA55209A (fr) | 2019-03-05 | 2022-01-12 | Prothena Biosciences Ltd | Procédés de traitement de l'amylose al |
| EP4022062A1 (en) * | 2019-08-30 | 2022-07-06 | Alnylam Pharmaceuticals, Inc. | Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy |
| EP4168451A2 (en) * | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| TW202332465A (zh) * | 2021-01-29 | 2023-08-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| WO2009086539A2 (en) | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| BR112014009866A2 (pt) | 2011-10-25 | 2018-09-04 | Onclave Therapeutics Limited | formulações de anticorpos e métodos |
-
2017
- 2017-06-30 RS RS20220716A patent/RS63446B1/sr unknown
- 2017-06-30 DK DK17740200.5T patent/DK3478713T3/da active
- 2017-06-30 MA MA045552A patent/MA45552A/fr unknown
- 2017-06-30 PL PL17740200.5T patent/PL3478713T3/pl unknown
- 2017-06-30 ES ES17740200T patent/ES2914781T3/es active Active
- 2017-06-30 PT PT177402005T patent/PT3478713T/pt unknown
- 2017-06-30 HR HRP20220979TT patent/HRP20220979T8/hr unknown
- 2017-06-30 US US16/314,143 patent/US20190169280A1/en not_active Abandoned
- 2017-06-30 WO PCT/US2017/040289 patent/WO2018005967A1/en not_active Ceased
- 2017-06-30 JP JP2018568771A patent/JP2019519584A/ja not_active Withdrawn
- 2017-06-30 SI SI201731146T patent/SI3478713T1/sl unknown
- 2017-06-30 HU HUE17740200A patent/HUE059400T2/hu unknown
- 2017-06-30 LT LTEPPCT/US2017/040289T patent/LT3478713T/lt unknown
- 2017-06-30 EP EP17740200.5A patent/EP3478713B1/en active Active
- 2017-06-30 SM SM20220261T patent/SMT202200261T1/it unknown
-
2020
- 2020-09-25 US US17/032,884 patent/US20210079078A1/en not_active Abandoned
-
2022
- 2022-07-01 JP JP2022106974A patent/JP2022121658A/ja not_active Withdrawn
- 2022-08-08 CY CY20221100542T patent/CY1125536T1/el unknown
-
2024
- 2024-07-04 JP JP2024108049A patent/JP2024127990A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019519584A (ja) | 2019-07-11 |
| SI3478713T1 (sl) | 2022-06-30 |
| EP3478713B1 (en) | 2022-05-11 |
| PT3478713T (pt) | 2022-05-27 |
| HRP20220979T1 (hr) | 2022-11-11 |
| MA45552A (fr) | 2019-05-08 |
| US20210079078A1 (en) | 2021-03-18 |
| JP2024127990A (ja) | 2024-09-20 |
| RS63446B1 (sr) | 2022-08-31 |
| HUE059400T2 (hu) | 2022-11-28 |
| DK3478713T3 (da) | 2022-06-20 |
| US20190169280A1 (en) | 2019-06-06 |
| EP3478713A1 (en) | 2019-05-08 |
| WO2018005967A1 (en) | 2018-01-04 |
| PL3478713T3 (pl) | 2022-10-10 |
| JP2022121658A (ja) | 2022-08-19 |
| LT3478713T (lt) | 2022-06-10 |
| ES2914781T3 (es) | 2022-06-16 |
| HRP20220979T8 (hr) | 2023-02-03 |
| SMT202200261T1 (it) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124730T1 (el) | Αντισωματα εναντι pd-1 και χρησεις αυτων | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1124955T1 (el) | Pd-1 αντισωματα | |
| CY1122981T1 (el) | Συνθεσεις για διαμορφωση της εκφρασης του c9orf72 | |
| CY1124153T1 (el) | Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 | |
| CY1124360T1 (el) | Αντισωματα aντι-il-33 και χρησεις αυτων | |
| CY1121723T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
| CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
| MX388015B (es) | Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer. | |
| JOP20200132A1 (ar) | صيغة مجففة بالتبريد من جسم مضاد أحادي النسيلة ضد ترانس ثيرتين | |
| CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
| BR112017018954A2 (pt) | uso de forma mutante de proteína ras e método para tratar câncer | |
| CY1121806T1 (el) | Ιμιδαζοπυραζινονες ως αναστολεις pde1 | |
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| FI3773689T3 (fi) | Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon | |
| EA202192101A1 (ru) | Соединения и их применение | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| IL281605A (en) | B*44 restricted peptides for use in immunotherapy against cancers and related methods |